bispecific-antibody-developability-risk-assessment
Bispecific antibodies are complex, often prone to issues that can delay development. Learn practical strategies to identify and mitigate bispecific antibody developability risks early, ensuring a stable and effective product.
Menu
Thinking Ahead: A Practical Guide to Bispecific Antibody Developability
Current Situation
Typical Market Trends
Current Challenges and How They Are Solved
How Leukocare Can Support These Challenges
Value Provided to Customers
Frequently Asked Questions (FAQ)
Thinking Ahead: A Practical Guide to Bispecific Antibody Developability
Current Situation
Bispecific antibodies (bsAbs) are leading the way in new treatments, showing great promise in areas like oncology by engaging two different targets at once. [1, 8] This dual-targeting ability opens up new ways to fight complex diseases. [2, 3] Anyone involved in their development knows these molecules are far more complex than standard monoclonal antibodies (mAbs). [4] Their engineered structures, often combining fragments in novel ways, create unique hurdles in manufacturing and ensuring stability. [6] Addressing these challenges early is not just a technical detail; it's a must-do for any team looking to move a candidate from the lab to the clinic efficiently.
Typical Market Trends
The pipeline for bispecific antibodies is expanding rapidly, with some analysts predicting the market could reach over $50 billion by 2030. There are currently more than 600 bsAb candidates in clinical trials, the majority focused on cancer treatment. [1, 8] This growth is accompanied by an explosion in structural diversity, with well over 100 different formats being explored. This variety, while exciting, complicates development. Each new format can introduce its own set of challenges, from production to purification. [6] For teams under pressure to accelerate timelines, navigating this complexity to select a winning candidate is a big job. The push to get to the clinic quickly often means that critical chemistry, manufacturing, and controls (CMC) work is done in parallel, adding another layer of risk. [4]
Current Challenges and How They Are Solved
For a CMC or Drug Product Director, the path to a stable, effective bispecific antibody is filled with potential setbacks. These molecules are often prone to issues that can delay or even halt development.
Aggregation: The novel structures of bsAbs can expose hydrophobic regions, making them susceptible to clumping together. [10] Aggregation is a serious concern, as it can affect the drug's effectiveness and pose safety risks. [12]
Instability and Impurities: The complexity of pairing different antibody chains correctly can lead to a high percentage of incorrectly assembled molecules, fragments, and other impurities. [4, 6] These impurities are often difficult to remove and can compromise the final product. [6]
High Viscosity: Many bsAbs are developed for subcutaneous injection, which requires high protein concentrations. [13] At these concentrations, solutions can become too thick to manufacture or inject easily, creating big problems for both processing and patient administration. [15, 16, 17]
The Developability Question: With so many potential candidates and formats, the biggest challenge is often deciding which one to advance. Early assessment of a molecule's "developability," or its likelihood of becoming a stable and manufacturable drug, is essential for avoiding costly late-stage failures. [18]
Today, these problems are often tackled with a mix of computational screening tools and high-throughput lab experiments. [20] This screening often happens after a lead candidate has already been selected based on its biological function. Formulation development, which is key to solving stability and viscosity problems, is frequently treated as a downstream step. This reactive approach means that fundamental flaws in a molecule might not be discovered until significant time and resources have been invested, leading to difficult decisions and program delays.
How Leukocare Can Support These Challenges
A different approach is needed, one that integrates formulation science from the very beginning. Thinking about the final drug product during the initial candidate selection process can dramatically reduce risk. This is where a strategic partnership can make a real difference.
Instead of waiting for problems to arise, we focus on predicting and preventing them. By applying our AI-based modeling and deep biophysical understanding early on, we can help you assess the risks they naturally have as your lead candidates. This allows you to compare different molecules not just on their biological activity, but on their probability of becoming a successful drug product.
Our process is designed to provide clear, data-driven answers to your most important questions. We can help you understand which candidate is less likely to aggregate, which will behave better at high concentrations, and which formulation strategy will give you the best chance of success. This proactive approach helps build a strong CMC story, which is essential for both internal stakeholders and regulatory bodies. It turns formulation from a late-stage hurdle into an early-stage strategic advantage. [4]
Value Provided to Customers
Safer Timelines: By identifying potential formulation and stability issues before they become major problems, you can avoid costly delays and shorten the path to filing an IND.
Increased Confidence in Your Candidate: A data-driven formulation strategy provides a strong basis for your development program. It gives your team, your board, and regulators confidence that your molecule is built on a strong scientific and regulatory basis. [23]
A True Development Partner: We understand that every project is different. Whether you are a virtual company needing specialized skills or a mid-sized biotech with an established team, we work as a collaborative partner. We can take on specific challenges, like a novel modality, or provide the support needed to manage overflow projects, allowing your internal team to stay focused. Our goal is to provide the targeted support you need, without friction. [25]
Frequently Asked Questions (FAQ)
Q1: At what stage should we start thinking about formulation for a bispecific antibody?
A: The earlier, the better. Introducing formulation and developability assessments during candidate selection can guide you toward molecules with a higher probability of success. Early data can prevent significant rework down the line. [18]Q2: Our bispecific has a completely new format. Can you still help?
A: Yes. Our approach is built on understanding the fundamental biophysical principles that govern protein stability, regardless of the specific format. We analyze the properties of your unique molecule to design a tailored solution, rather than relying on a one-size-fits-all platform approach. [10, 12]Q3: We already have an internal drug product team. How do you work with them?
A: We act as a specialized resource to support your existing team, not replace them. We can take on complex challenges that require specialized skills, such as a new modality or a difficult stability issue. This frees up your internal team to focus on their primary responsibilities.Q4: We are a virtual company with limited in-house resources. Is this approach right for us?
A: Absolutely. We are structured to function as your dedicated formulation and drug product specialists. We provide the deep expertise and strategic guidance you need to build a robust CMC package without the expense of building a large internal team.
Sources
[12] Formulations That Suppress Aggregation During Long-Term Storage of a Bispecific Antibody are Characterized by High Refoldability and Colloidal Stability - PubMed. (n.d.). Retrieved August 8, 2025, from https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGEkTafphy5jgHfngtECT5hk3NLdD2c3_36NoRhtKLi-wNdgWOC5kYGoD36o_Lk0ZCcmCodqOa4u4PEDDcJNCHBLjCqsiNeUJeHE2_9baVIfTIqBRCD0qPeV1Z4owL6lYN1PD0=
[26] Bispecific Antibodies Clinical Trials and Pipeline Analysis. (n.d.). Retrieved August 8, 2025, from https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeNeCU56eyY_0-S4JwhFArbS-rOY7vjuAG7gRzn_kE_dB8CzB_1UjOnHEQwJacWgMY3biWR1Muu3aPoVKy1Wb8mhDQK-iGAik2qIAHjw3pcrSwEtu7remVwFG9lW_qLcFDBkoLQQY5stHJK1uFV591RNs9v7f_eYXUm3eNabZPskCStLwV_vjkk2ls8zo0p7pRt0TlQ==
[27] Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight. (2023, July 3). PR Newswire. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9rImfD7mNzT5ia_bocL7KNMJBEVoVwdEBYAjwzJ4VowUp--kIBDqKIkPGCP97BJvpIU3J-b4SdgMCmlPpBo4KJfInIwPzzZXVU54QTMmhRDTB3342Tlh6tlIsEAo7-IO2LXgSvOrt4EtcjwcpGsA0y4jdUxS7wkYMN9uc8FLnvFDOFPGHolEhNIpBrhlEX39TPgOp63xkv-YIqIxSb9WON8KtllwNC6KRU-iWhaHoY2o-0cVA2MraVsNT8PrY7GP5FUqZcGju2X0i47G34HD-F5LWJp-PB5IkDBtL_pURe_lxAczLPWNnEKmUkLe2xeoDpn-yAhXsLOnpvdKZ0jsCP-qkYUx
[28] Next-Generation Bispecific Antibody Market Trends and Opportunities. (2025, June 13). Towards Healthcare. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHuaSA5GH1OMptNnkfmCkskx5TJof4eTus7ADxvxqeB1vT2s-yILh39X1XB6UeRqxQFeoBCQ6hfdWyrzd_de1noA1DRbpXJsgvOuSq8Fowwj-p5BhmSM4E80Qcu5mUQmGnfQ_SFbq6xi8hKg73vgsJKIocaUCzG2WWKhWakyQ2U-s3v8TpspU2JUbSvIkz-QLIQ4kWIOgY=
[20] Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods. (n.d.). Springer Nature Experiments. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDNqWUc3m33pux1KCkzeSbqFUJM3dA2FgsPGbsfH_zSnu-RNiXPriFDcC61Q94bZJT6RGBv_K3CfllR1bbv9tuaNNYb280EzsiorfVwFdJEWGx_e43NNyFv1yGt4lDUz2458QrqsmVYfdmT6XdB_P49fVEP5_zRusDgs79b6dChI9dFeSs
[10] Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates. (2024, August 23). https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFHBSP2x2GduEWhD-bEebI5qIm9w_nEMkm7EaH-LLcjIQPhUvTusnt3ks3udtJmaWCKniFZj1PJoMxckXuo6VXuPNnNjbUJWXgykraK9yjNfu31uzfIf1wkRFWn6MBMeG6_wVwLCGhd0i4Jm4=
[23] Hazard identification and risk assessment for biologics targeting the immune system. (n.d.). Retrieved August 8, 2025, from https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJHpmd7CzS4Sxp8qxuJBjUO77067TLrTrEeb5d896KHpyGlW_GrDUSdL1pmamL6YxEx2SUAVATJ6n1tVv7FA0K1XCB58DSyCPaMtR-L4l25nRCVR7I1U-JxsP6ovXmdhokPUc=
[18] Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods - PubMed. (n.d.). Retrieved August 8, 2025, from https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOc33x_mrqBm_qK27SpQ3EWDpwEPjW0RIwlX9btcKbGbIjJ8B6sWIpdP_JTQKAAe5f-EMUpXRWLHRT3x1IsjtzQHjpUR7pN3khsLzpTUxdueWy-lCLoouecHIsIpBEGh7JVus=
[4] CMC Strategies For The Development Of A Bispecific Antibody Platform for Cancer Immunotherapy. (n.d.). Bioprocess Online. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv6NlObFj7AtiEeLc0sjZd7emy-gWI5BcSBvXAfvObduK0tE3zJbSE1rm3JfdaXuXxBgctSSZ-9RwTpxna2-6pXY2-wu95w1C8EtgJZcV4u5B7GWJO_z8eawY6DKZCcDSXk2mTt1lHywP5cd4Lmu52P3YM_CxGdPt8kjsyx8ccNb60ogxINmbxJBviWJgDd4qaC7VTGMEengAsIlfxGSANmsp5K6qDYOPpznZqPqHAZRtV-w2-_KBmZz32C3eZiB9oRQ==
[13] High Concentration Biologic Formulations: Challenges and Solutions. (2017, June 29). Retrieved August 8, 2025, from https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFro1GuxYS4Dhoi4MBQEEbBaYdchLLVXegZKsWIHohbkKv6d3N_twIgT2GsJ_51eL1IT42M_o9Nb-1td5e6mnmSodTYQ-iex9ZPP_vNOXxTs2Wyf1IzJbMnLfQDnMdnk52mx56fbVE_YYRClifyiqo3dRvLy8vS-iQG_ZyEF0VLewzPUEUdKIh8ua8JljoPtCzDzTnDXL0DpA3S-KmPa0p
